Bryan Steadman

Biography

 Bryan Steadman joined Universal Cells Inc. in Feb 2017 as the Chief Technology Officer responsible for the translation of R&D to GMP activities and leadership of the Quality, Regulatory, Process Development and Manufacturing Operations.  Most recently, Bryan was the Executive Director Process Development at Amgen helping transform biotechnology manufacturing by leveraging new internal and external technology development into an integrated facility design.  Prior to Amgen, Bryan was VP CMC Operations for LigoCyte, a VC funded biotechnology firm in Bozeman MT that was acquired by Takeda.   In total, he has more than 25 years of technical experience having also worked at Merck, Bristol-Meyers Squibb and Allergan in technical and management roles. Bryan has a PhD in Environmental Toxicology and BS in Microbiology, both from the University of Wyoming.

Research Interest

 Oncology